Goldman Sachs
CLPT icon

Goldman Sachs’s ClearPoint Neuro CLPT Stock Holding History

Goldman Sachs’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.22M Buy
463,617
+173,273
+60% +$2.19M ﹤0.01% 3876
2025
Q4 		$3.97M Buy
290,344
+185,237
+176% +$3.43M ﹤0.01% 3953
2025
Q3 		$2.29M Sell
105,107
-181,685
-63% -$2.14M ﹤0.01% 4358
2025
Q2 		$3.42M Buy
286,792
+28,921
+11% +$364K ﹤0.01% 3765
2025
Q1 		$3.07M Buy
257,871
+127,823
+98% +$1.99M ﹤0.01% 3816
2024
Q4 		$2M Buy
130,048
+100,898
+346% +$1.31M ﹤0.01% 4278
2024
Q3 		$327K Sell
29,150
-97,434
-77% -$933K ﹤0.01% 5264
2024
Q2 		$682K Buy
126,584
+80,297
+173% +$465K ﹤0.01% 4656
2024
Q1 		$315K Sell
46,287
-277
-0.6% -$1.94K ﹤0.01% 4951
2023
Q4 		$316K Sell
46,564
-718
-2% -$4.06K ﹤0.01% 4976
2023
Q3 		$237K Buy
+47,282
New +$281K ﹤0.01% 4981
2023
Q2 		– Sell
-102,838
Closed -$868K – 5787
2023
Q1 		$868K Buy
102,838
+59,953
+140% +$525K ﹤0.01% 4481
2022
Q4 		$363K Buy
42,885
+7,206
+20% +$68.3K ﹤0.01% 5043
2022
Q3 		$370K Sell
35,679
-9,237
-21% -$122K ﹤0.01% 5172
2022
Q2 		$586K Sell
44,916
-10,752
-19% -$110K ﹤0.01% 4972
2022
Q1 		$580K Buy
55,668
+13,870
+33% +$126K ﹤0.01% 5217
2021
Q4 		$469K Sell
41,798
-68,963
-62% -$1.03M ﹤0.01% 5428
2021
Q3 		$1.97M Buy
110,761
+64,711
+141% +$1.21M ﹤0.01% 4214
2021
Q2 		$879K Buy
46,050
+21,018
+84% +$406K ﹤0.01% 4857
2021
Q1 		$529K Buy
+25,032
New +$536K ﹤0.01% 5074
2019
Q4 		– Sell
-33,206
Closed -$168K – 5229
2019
Q3 		$168K Buy
+33,206
New +$136K ﹤0.01% 4862

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs's CLPT Position: Q1 2026 in Review

Goldman Sachs increased its ClearPoint Neuro (CLPT) stake by 60% in Q1 2026, buying an estimated $2.19M and bringing the position to 463,617 shares worth $4.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3876.

Goldman Sachs first reported a position in CLPT in Q3 2019 and has held it in 21 quarters since. 118 funds tracked by Wall St. Rank hold CLPT as of Q1 2026.

  • Goldman Sachs held 463,617 shares of ClearPoint Neuro worth $4.22M as of Q1 2026.
  • Goldman Sachs bought 173,273 ClearPoint Neuro shares in Q1 2026, an estimated $2.19M.
  • ClearPoint Neuro made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3876 holding.
  • Goldman Sachs first reported a position in ClearPoint Neuro in Q3 2019 and has held it in 21 quarters since.
  • 118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.